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ABSTRACT
The regulation of microtubule dynamics is critical to ensure essential cell 
functions. End binding protein 1 (EB1) is a master regulator of microtubule dynamics 
that autonomously binds an extended GTP/GDP-Pi structure at growing microtubule 
ends and recruits regulatory proteins at this location. However, negative regulation 
of EB1 association with growing microtubule ends remains poorly understood. We 
show here that microtubule-associated tumor suppressor ATIP3 interacts with EB1 
through direct binding of a non-canonical proline-rich motif. Results indicate that 
ATIP3 does not localize at growing microtubule ends and that in situ ATIP3-EB1 
molecular complexes are mostly detected in the cytosol. We present evidence that 
a minimal EB1-interacting sequence of ATIP3 is both necessary and sufficient to 
prevent EB1 accumulation at growing microtubule ends in living cells and that EB1-
interaction is involved in reducing cell polarity. By fluorescence recovery of EB1-
GFP after photobleaching, we show that ATIP3 silencing accelerates EB1 turnover at 
microtubule ends with no modification of EB1 diffusion in the cytosol. We propose a 
novel mechanism by which ATIP3-EB1 interaction indirectly reduces the kinetics of 
EB1 exchange on its recognition site, thereby accounting for negative regulation of 
microtubule dynamic instability. Our findings provide a unique example of decreased 
EB1 turnover at growing microtubule ends by cytosolic interaction with a tumor 
suppressor.
INTRODUCTION
Microtubules (MTs) are polarized structures that 
continuously switch between periods of polymerization 
and depolymerization at their growing (plus) ends. This 
process, termed MT dynamic instability, allows rapid 
reorganization of the MT cytoskeleton during essential 
cell functions such as cell polarity and migration, mitosis 
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and intracellular transport of proteins and organelles. 
Alterations in MT dynamic instability parameters lead 
to defects in MT targeting, mitotic spindle formation and 
chromosome segregation, with subsequent consequences 
on cancer initiation and progression.
MT dynamic instability is tightly regulated by 
microtubule-associated proteins (MAPs) and plus-end 
tracking proteins (+TIPs) that accumulate at growing 
MT plus ends [1, 2]. End-Binding protein EB1 is a 
+TIP that plays a pivotal role in orchestrating protein 
interaction networks at growing MT ends. EB1 binds 
MTs with its N-terminal calponin homology (CH) domain 
and displays in its C-terminal portion an EB homology 
(EBH) domain responsible for interaction with a wide 
variety of regulatory +TIPs. EB1-recruited proteins 
contain either a cytoskeleton-associated protein glycine-
rich domain (CAP-Gly) or a consensus sequence SxIP 
(serine - any aminoacid - isoleucine - proline) embedded 
in an intrinsically unstructured polypeptide region rich 
in basic, proline and serine residues [2-6]. In addition 
to its role as a molecular platform for regulatory +TIPs, 
EB1 has an intrinsic regulatory effect on MT dynamics 
at growing ends. EB1 senses the nucleotide state of MTs 
and is able to bind autonomously an extended GTP/GDP-
Pi cap structure at the MT end [7-9] with more than 10-
fold higher affinity compared to the microtubule lattice 
[8]. Measurements of EB1 protein dynamics showed that 
they exchange very rapidly at growing MT ends with fast 
binding/unbinding kinetics [10-12]. In mammalian cells 
[13] and Xenopus extracts [10], EB1 has been shown to 
increase persistent MT growth and suppress catastrophe 
frequency. Recent in vitro studies have identified EB1 as 
a MT maturation factor that decreases the maturation time 
of growing MT ends [14], providing a mechanistic link 
between EB1 localization and regulation of MT dynamics. 
However, negative regulation of EB1 association with MT 
growing ends, which is essential to EB1 function, remains 
poorly understood.
ATIP3 is a novel MAP encoded by candidate tumor 
suppressor gene MTUS1 whose expression is markedly 
down-regulated in a variety of human cancers [15-17]. 
ATIP3 re-expression at normal levels into breast cancer 
cells significantly reduces cell proliferation, tumor growth 
and metastatic dissemination in animal models [15, 17] 
underlying important tumor suppressor effects. ATIP3 
also limits cell migration by decreasing cell polarity and 
directionality, and impairs the ability of MTs to reach the 
cell cortex as a consequence of reduced MT dynamics at 
the plus ends [17]. Conversely, ATIP3 depletion increases 
MT dynamic instability by increasing MT growth and 
growth rate, and decreasing catastrophe frequency and 
time spent in attenuated state [17]. Interestingly, the 
effects of ATIP3 deficiency on MT dynamic instability 
parameters are superimposable to those observed upon 
EB1 expression in living cells, leading us to investigate 
whether ATIP3 may negatively regulate EB1 functions at 
growing MT ends.
In the present study, we show that ATIP3 interacts 
with EB1 in an MT-independent manner. The interaction 
involves a non-canonical sequence that directly binds EB1 
in vitro. ATIP3-EB1 complexes are present in the cytosol 
and impair EB1 accumulation at growing MT ends. 
FRAP analyses indicate that ATIP3 deficiency increases 
the dynamic exchange of EB1 at growing ends with no 
modification of EB1 diffusion in the cytosol. Our results 
support a novel model for negative regulation of EB1 
turnover at MT plus ends.
RESULTS AND DISCUSSION
ATIP3 interacts with EB1
To investigate whether ATIP3 interacts with EB1, 
we used anti-mCherry (mCh) antibodies to isolate mCh-
ATIP3 complexes from MCF7 cells expressing mCh-
ATIP3 fusion protein and EB1 fused to green fluorescent 
protein (EB1-GFP). Western blotting with anti-GFP 
antibodies confirmed the presence of a mCh-ATIP3-EB1-
GFP complex (Figure 1A, upper panel). In a reciprocal 
experiment, mCh-ATIP3 was detected by anti-mCh 
antibodies following immunoprecipitation of EB1-GFP 
(Figure 1A, middle panel) as well as GFP-EB3 and 
EB3-GFP (Supplementary Figure S1A), indicating that 
ATIP3 is able to bind EB1 and EB3 in intact cells. Of 
note, ATIP3-EB1 complexes were not detectable by co-
immunoprecipitation of endogenous proteins expressed in 
HeLa cells, suggesting that the interactions between these 
proteins are weak or transient and/or involve a fraction of 
the proteins. 
GST pull-down assays were performed using 
GST-EB1 as an affinity matrix. As shown in Figure 1B, 
GST-EB1, but not GST, precipitated GFP-ATIP3 fusion 
proteins as well as endogenous ATIP3 expressed in HeLa 
cells (Figure 1C). Full-length ATIP3 was then cleaved into 
three regions designated D1, D2 and D3 (Figure 1D) that 
were fused to GFP. Pull-down experiments using GST-
EB1 (Figure 1E) revealed that only the central (D2) region 
is retained on GST-EB1 beads. Of note, the C-terminal 
D3 region does not interact with EB1 although it contains 
a bona fide SxIP motif embedded in an intrinsically 
unstructured polypeptide region rich in basic, proline 
and serine residues (Supplementary Figure S1B), which 
is a hallmark of EB1 binding [3, 5, 18]. Accordingly, 
deleting the last 30 residues of ATIP3 (DelCTer mutant) 
did not abrogate EB1 binding (Supplementary Figure 
S1C). Furthermore, EB1 binding was not affected by 
replacement of core hydrophobic residues of the consensus 
SAIP motif with polar residues (Ile and Pro at positions 
1251-1252 of the ATIP3 sequence changed to Asn and Ala, 
respectively) in SANP and SAIA mutants (Supplementary 
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Figure 1: ATIP3 interacts with EB1. A. MCF7 cells were transfected with mCh-ATIP3 (or mCh) and EB1-GFP (or GFP) and 
immunoprecipitation was performed using anti-GFP or anti-mCh antibodies as indicated. Western blots were probed with anti-MTUS1 and 
anti-GFP antibodies to reveal mCh-ATIP3 (210 KDa) and EB1-GFP (55 KDa). IgGH: Immunoglobulin heavy chain. B. GST pull-down 
assays of MCF7 cell lysates transiently expressing GFP-ATIP3 or GFP using GST or GST-EB1 beads as indicated. Blots were probed with 
anti-GFP antibodies. An asterisk indicates cleavage product of GFP-ATIP3. Lower panel: GST beads loading. C. Purified GST-EB1 beads 
were used to precipitate GFP-ATIP3 (210 KDa) and endogenous ATIP3 (180 KDa) expressed in HeLa cells. Blots were probed with anti-
MTUS1 antibodies. Lower panel: GST beads loading. D. Schematic representation of ATIP3 protein illustrating the position of D1, D2 and 
D3 regions. CC: coiled coil region. Position of the SAIP motif (residues 1249-1252) is shown. Amino acid numbering is from Accession 
number NP_001001924. Lower panel: Schematic drawing of ATIP3 deletion mutants and their ability (+) or not (-) to bind EB1 and MTs. 
E. GST-pull-down assays of MCF7 cell lysates expressing GFP-fused D1, D2, D3 regions as in B. F. Pull-down assays of MCF7 cell lysates 
expressing GFP-ATIP3 or GFP-D2, using GST-EB1, GST-EB1-C and GST-EB1-N as indicated (left panel) or following treatment with 10 
µM nocodazole (Nz) or vehicle (Ctrl) for 1h at 4°C (right panel). Blots were probed as in B. G. Pull-down analysis of GFP-D2 fragments 
using GST and GST-EB1 beads as in B. Molecular weights (KDa) are on the left. H. Pull-down analysis of ATIP3 deletion mutants using 
GST-EB1. Blots were probed with anti-GFP antibodies as in B. Lower panel : GST beads loading. I. In vitro pull-down assay using GST 
(white bars) or GST-EB1 (black bars) beads and 10 or 15 µg of synthetic fluorescent CN45 and CC peptides as indicated below. Upper 
panel: fluorescence intensity (arbitrary units) in the precipitates. Lower panel: fluorescence was detected in samples before (input) and after 
GST pull-down, using Typhoon scanner following resolution on 15%SDS-PAGE.
Oncotarget4www.impactjournals.com/oncotarget
Figure S1C), further indicating that the canonical SxIP 
motif of ATIP3 is not essential to EB1 interaction.
To map the domain of EB1 that interacts with 
ATIP3, we used GST-EB1 deletion mutants comprising 
either the N-terminal (EB1-N) or C-terminal (EB1-C) 
portion of the molecule [20]. As shown in Figure 1F (left 
panel), both ATIP3 and D2 interact with the C-terminal 
region of EB1, as do other EB1 partners [1-6]. Of note, D2 
still binds GST-EB1-∆Ac (Supplementary Figure S1D), an 
EB1 deletion mutant that lacks the last 19 amino acids and 
does not interact with SxIP-containing proteins [5, 19], 
suggesting that the mode of interaction between EB1 and 
ATIP3 differs from that of EB1-SxIP partners. 
To evaluate whether MTs may contribute to ATIP3-
EB1 binding, cells were treated with nocodazole at a 
concentration that totally depolymerizes cellular MTs. In 
these conditions, ATIP3 and D2 still bound EB1 (Figure 
1F, right panel), indicating that EB1-ATIP3 interaction 
does not require an intact MT network.
To map further the EB1-interacting region of ATIP3, 
a series of deletion mutants (Figure 1D) were analyzed in 
GST-EB1 pull-down experiments. As shown in Figure 1G 
(upper panel) D2C and CN fragments retained the ability 
to interact with EB1. Deletion of the CN sequence in 
ATIP3 and D2 polypeptides (ATIP3delCN and D2delCN 
mutants) led to a marked decrease in EB1 interaction 
(Figure 1H) whereas deleting the adjacent CC sequence 
(delCC1, delCC2, D2delCC1 mutants) did not abrogate 
EB1 binding (Supplementary Figure S1E). The EB1-
interacting region was further refined to sequences of 
67 and 45 amino acids (CN67 and CN45, respectively) 
(Figure 1G, lower panel). The minimal EB1-interacting 
sequence CN45 is evolutionary conserved (Supplementary 
Figure S1F) and includes a proline-rich motif whose 
deletion (Del3P mutant) markedly reduced EB1 binding 
(Figure 1H).
To investigate whether the interaction is direct, a 
fluorescent peptide corresponding to the CN45 sequence 
was synthesized and analyzed in GST-EB1 pull-down 
assays in vitro. The CC sequence, that does not bind EB1, 
was used as a negative control. As shown in Figure 1I, 
FITC-CN45 (but not FITC-CC) was specifically retained 
on GST-EB1 beads, indicating direct interaction between 
CN45 and EB1 and suggesting that ATIP3 might bind EB1 
directly. Altogether, these results demonstrate that ATIP3 
interacts with EB1 via a non-canonical motif present in the 
C-terminal part of the D2 sequence. 
EB1-interaction and MT-binding involve different 
ATIP3 regions
To evaluate whether EB1-interaction and MT-
binding may involve the same region of ATIP3, we 
analyzed the cellular localization of GFP-fused D2 
deletion mutants by immunofluorescence. As shown 
in Figure 2, both N-terminal (D2N) and C-terminal 
(D2C) portions of D2 co-localized with tubulin along 
the MT lattice. Shorter deletion mutants of D2C (CN 
and CC) remained mostly cytosolic, suggesting that MT 
localization involves a conformational recognition motif 
that requires both parts of the sequence. Importantly, the 
EB1-interacting domain CN was diffuse in the cytosol 
whereas the D2delCN deletion mutant, that has lost 
EB1 binding, still decorated the MT lattice (Figure 2, 
Supplementary Table S1), indicating that EB1-interaction 
is independent of MT-binding and that the two interacting 
regions are not overlapping. 
ATIP3-EB1 complexes are present in the cytosol
The interaction between ATIP3 and EB1 prompted 
us to examine whether EB1 may recruit ATIP3 at growing 
MT plus ends. We used RPE-1 cells that have a sparse MT 
array and are well suited for visualizing individual MTs 
and MT ends [17]. Cells were transfected with levels of 
GFP-ATIP3 close to endogenous, to avoid MT bundling 
due to ATIP3 overexpression [17]. As shown in Figure 
3A, EB1 comet-like structures were still detectable in 
low GFP-ATIP3-expressing cells and GFP-ATIP3 was 
distributed along the MT lattice but did not co-localize 
at MT ends together with endogenous EB1. Time-lapse 
analysis (Supplementary Figure S2A, Movies 1 and 2) 
also clearly showed distinct patterns of mCh-ATIP3 and 
EB3-GFP localization in living cells and indicated that 
ATIP3 does not accumulate at growing MT ends. Finally, 
time-lapse images of MCF7 cells stably expressing 
moderate levels of GFP-ATIP3 (Supplementary Figure 
S2B, Supplementary Movie 3) confirmed that ATIP3 
decorates the MT lattice and has no tip-tracking properties. 
Interestingly, they also revealed for the first time that 
ATIP3 accumulates at the end of shrinking microtubules 
in living cells, highlighting its back-tracking behavior.
To reveal the location of ATIP3-EB1 complexes 
inside the cells, we used the Proximity Ligation Assay 
(PLA) duolink technology that allows in situ detection 
of molecular complexes in single cells at the location 
where the proteins of interest interact [21]. Molecular 
proximity between endogenous ATIP3 and EB1 proteins 
was assessed in HeLa cells using anti-MTUS1 and anti-
EB1 primary antibodies followed by in situ detection of 
fluorescent Rolling Circle amplification Products (RCP). 
Individual bright fluorescent RCP signals were detected 
in control cells but not following transfection with ATIP3- 
or EB1-siRNA (Figure 3B). Red RCP signals indicating 
molecular proximity between endogenous ATIP3 and EB1 
proteins were distributed throughout the cytosol (Figure 
3B) and were found to some extent to colocalize with the 
MT lattice (Figure 3B, inset).
PLA amplification signals were also detected using 
anti-GFP and anti-EB1 primary antibodies in RPE-1 
cells expressing GFP-ATIP3 and GFP-D2, but not 
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GFP-D1 (Figure 3C) nor in negative control conditions 
(Supplementary Figure S3A, S3B and S3C). Specific PLA 
signals were also revealed in mCh-ATIP3-transfected 
RPE-1 cells stably expressing EB1-GFP using anti-
Figure 2: Cellular localization of GFP-D2 and deletion mutants. Immunofluorescence imaging of RPE-1 cells expressing 
GFP-D2 and GFP-tagged deletion mutants as indicated. Cells were fixed and stained with anti-GFP (green), anti-alpha-tubulin (red) 
antibodies and DAPI (blue). Enlarged portions of the selected areas are shown in the insets. Red arrowheads show MT-localization of GFP-
fusion proteins. Scale bar, 10µm. 
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Figure 3: In situ interaction between ATIP3 and EB1. A. RPE-1 cells transfected with low amounts of GFP-ATIP3 were fixed and 
stained with anti-GFP (green) and anti-EB1 (red) antibodies. Insets show that EB1 comet-like structures at plus ends are not stained by GFP-
ATIP3. Magnification 100X. Scale bar 10µm. B. PLA performed in HeLa cells transfected with control (siCtrl), ATIP3-specific (siATIP3) 
or EB1-specific (siEB1) siRNA as indicated. Silencing efficiency was assessed by immunoblotting with anti-MTUS1 (ATIP3), anti-EB1 
and anti-tubulin (Tub) antibodies. Molecular proximity between endogenous ATIP3 and EB1 was analyzed using rabbit anti-MTUS1 and 
mouse anti-EB1 primary antibodies and revealed as red signals of RCP stained with cy5-labeled oligonucleotide probe. Cells were stained 
with anti-alpha-tubulin antibodies to reveal the MT network. Shown are merge pictures of tubulin (green), RCP (red) and nuclei (blue) 
staining. Scale bar 10µm. Inset: enlarged portion of a selected area from siCtrl-transfected cell. The arrowhead illustrates alignment of RCP 
signals along the MT lattice. Right panel: quantification of the number of RCP per area (100 µm2). Number of areas analyzed (5 areas from 
at least 6 different cells in 3 independent experiments) is under brackets. ***p < 0.0001. C. PLA performed in RPE-1 cells transfected with 
GFP-tagged ATIP3 regions and deletion mutants as indicated on the left, using rabbit anti-GFP and mouse anti-EB1 primary antibodies. 
Shown are merge pictures of GFP (green), RCP (red) and nuclei (blue) staining. Scale bar 10µm. Inset: enlarged portions of selected areas. 
Arrowheads illustrate alignment of RCP signals along the MT lattice. D. Quantification of the number of RCP per area (100 µm2) as in B. 
Five areas from at least 6 single cells in 3 independent experiments were analyzed. ***p < 0.0001.
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mCh and anti-GFP primary antibodies (Supplementary 
Figure S3D). In line with GST-EB1 pull-down assays, 
PLA analyses revealed the presence of in situ molecular 
complexes between endogenous EB1 and GFP-D2C 
and GFP-CN, but not GFP-D2N and GFP-CC regions 
(Supplementary Figure S3E). The number of in situ 
PLA amplification signals was markedly reduced in cells 
transfected with ATIP3delCN and D2delCN deletion 
mutants as compared to full-length ATIP3 and D2 region 
(Figure 3D), further demonstrating the involvement of the 
CN sequence in EB1-ATIP3 complex formation in intact 
cells. 
ATIP3 interacts with EB1 to limit its accumulation 
at growing ends
To investigate the consequence of ATIP3-EB1 
interaction on the accumulation of EB1 as comet-like 
structures at growing MT ends, which is a hallmark of 
MT dynamics, we analyzed EB1 staining in the presence 
of D2 and deletion mutants. As shown in Figure 4A, 
expression of EB1-interacting regions D2C and CN 
reduced the number and length of EB1 comets to the 
same extent as D2, whereas CC - that does not bind EB1 
- had no significant effect on EB1 comet-like structures. 
Of importance, deletion mutants (D2delCN and Del3P) 
having lost the ability to interact with EB1 were no 
longer able to reduce EB1 accumulation at growing MT 
ends (Figure 4A, Supplementary Table S1), highlighting 
functional relevance of ATIP3-EB1-interaction.
To validate our results, rescue experiments were 
performed on ATIP3-silenced HeLa cells in which GFP-
ATIP3 was re-introduced at levels close to endogenous 
(Supplementary Figure S4A). As expected, EB1 comets 
in ATIP3-depleted cells were significantly increased as 
compared to control, and moderate levels of GFP-ATIP3 
were sufficient to fully rescue the ATIP3 knock-down 
phenotype (Supplementary Figure S4B). Importantly, 
moderate expression of GFP-D2 and GFP-CN, but 
not GFP-D2delCN, in ATIP3-silenced HeLa cells was 
sufficient to restore EB1 comets (Supplementary Figure 
S4C, S4D and S4E) further confirming that ATIP3/EB1-
interaction is essential to the regulatory effects of ATIP3 
on EB1 comets formation. 
We then investigated the consequence of ATIP3 
silencing on the localization of EB1 partners such as 
CLIP-170 and the MCAK kinesin, that bind EB1 via a 
CAP-Gly and a SxIP motif, respectively [1, 2]. As shown 
in Supplementary Figure S5A and S5B, the number 
of GFP-CLIP-170 and GFP-MCAK comets that co-
localized with EB1 was increased in ATIP3-depleted 
cells, indicating that ATIP3 reduces the accumulation of 
EB1/+TIPs molecular complexes at growing MT ends. 
Of note, a MCAK-3E mutant that does not interact with 
EB1 [3] remained cytosolic in both control and ATIP3-
silenced cells (Supplementary Figure S5C), confirming 
that regulation of MCAK comets by ATIP3 requires 
EB1. Thus, by interacting with EB1, ATIP3 negatively 
regulates the association of EB1 molecular complexes at 
MT growing ends. This, in turn, may contribute to fine-
regulation of MT dynamics in the presence of ATIP3.
As a consequence of decreased MT dynamics, the 
ability of MT tips to reach the cell cortex was markedly 
impaired during cell migration, leading to defects in cell 
polarity in migrating D2-positive cells compared to control 
cells (Figure 4B). Deletion of the EB1-interacting domain 
(D2delCN mutant) restored a radial array of MTs at the 
cell margin and abrogated the effect of D2 on cell polarity, 
further illustrating the importance of EB1 interaction 
in ATIP3 function. Of interest, expression of the EB1-
binding region CN partially impaired MT organization and 
cell polarity (Figure 4B) but was not sufficient to fully 
recapitulate the effects of ATIP3 suggesting that other 
ATIP3 regions, possibly involved in MT binding, might 
also contribute to ATIP3 biological function.
ATIP3 silencing increases EB1-GFP exchange on 
MT ends
To get more insight into the mechanism by 
which ATIP3 negatively regulates EB1, we examined 
the consequence of ATIP3 depletion on the dynamic 
association of EB1 with MT plus ends. Fluorescence 
recovery after photobleaching (FRAP) experiments were 
performed on HeLa cells expressing EB1-GFP following 
transfection with either control or ATIP3-specific siRNA. 
Bleaching was done in the distal part of growing MT ends 
and recovery of EB1-GFP fluorescence was measured 
(Figure 5A, Supplementary Movie 4). After correction 
for cytoplasmic background and fluorescence decay, K 
recovery for the exchange of EB1-GFP on MT ends in 
control cells was 3.47±0.45 s-1 (half-life of association 
0.24±0.03 s), which is very close to values previously 
reported for EB3-GFP recovery on MT ends in COS-
7 cells (K recovery of 3.37 s-1, half-life of association 
0.20 s) [12]. As shown in Figure 5A and 5B, EB1-GFP 
fluorescence recovery at MT plus ends was significantly 
faster in ATIP3-silenced cells (K recovery of 5.23±0.66 
s-1, half-time of association 0.17±0.02 s), with no 
significant modification of EB1-GFP fluorescence decay 
(Supplementary Figure S6A), indicating that EB1 
exchange on its recognition site at growing MTs is 
increased in the absence of ATIP3. Of note, the lifetime 
of EB1-GFP labeled region on MT plus ends (EB1 
decoration time, that specifies EB1-interacting sites at 
MT ends) remained unchanged in ATIP3-deficient versus 
control cells (2.68 +/- 0.93 (n = 100) and 2.67 +/- 1.28 (n = 
70), respectively) (Supplementary Figure S6B), indicating 
that ATIP3 silencing does not alter EB1-recognition sites 
on MT ends. 
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Figure 4: Effect of deletion mutants on EB1 comet formation and cell polarity. A. Anti-EB1 (green) and anti-tubulin (red) 
immunostaining of RPE-1 cells transiently transfected with GFP-D2 and GFP-tagged regions. Insets: EB1 comet-like structures in enlarged 
portions of selected areas. Red arrowheads illustrate weak EB1 staining along the MT lattice. Right panels show distribution of EB1 (green) 
and alpha-tubulin (red) at the microtubule plus ends (linescans), and quantification of number of comets (per 62µm2 area) and comet 
length (scattered dot plot) from 5 single cells in 3 to 5 independent experiments. Number of comets analyzed is under brackets. NT: non-
transfected. Scale bar, 10µm. ***p < 0.0001. B. Immunofluorescence imaging of migrating MCF-7 cells transfected with GFP constructs 
as indicated. Cells were allowed to polarize for 3 hrs, then fixed and stained with anti-GFP (green), anti-α-tubulin (white) antibodies and 
DAPI (blue). Arrows indicate the direction of migration. Right panel shows quantification (percent) of polarized MCF-7 cells from 3 to 6 
fields, in 2 independent experiments. Number of cells analyzed is under brackets. Scale bar, 10µm. *p < 0.05; ***p < 0.0001.
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To investigate whether ATIP3 may impair EB1 free 
diffusion in the cytosol, which is rate limiting for EB1 
exchange at MT plus end [11, 12], EB1-GFP fluorescence 
recovery after photobleaching was measured in the cytosol 
of HeLa cells following ATIP3-silencing. As shown in 
Supplementary Figure S6C and S6D, ATIP3 depletion 
does not significantly modify EB1-GFP fluorescence 
recovery in the cytosol (K recovery of 2.2 ± 0.3 s-1 in 
control cells versus K recovery of 2.1 ± 0.6 s-1 in ATIP3 
silenced HeLa cells), ruling out a major effect of ATIP3 on 
EB1 mobility. Altogether, these results indicate that ATIP3 
binds EB1 in the cytosol to indirectly slower its binding/
unbinding kinetics on MT plus ends, without affecting free 
diffusion of EB1.
Figure 5: ATIP3 silencing increases EB1-GFP exchange on MT ends. A. Representative example of time lapse imaging of HeLa 
cells expressing EB1-GFP. Fluorescence was bleached at the distal part of the MT in control (siCtrl, upper) and ATIP3-silenced (siATIP3, 
lower) cells. Red arrowhead indicates position of the bleached comet. Fluorescence intensity of the bleached comet (middle panel) and 
fluorescence recovery curves (right panel) are shown. Red line in middle and right panels indicates fluorescence decay and recovery, 
respectively. B. Quantification of association time Tau in seconds (s), half-time of recovery in seconds (s), and krecovery (s-1) of fluorescence 
recovery in control cells (n = 17) and ATIP3-depleted cells (n = 16) in 2 independent experiments. Number of EB1-GFP bleached comets 
analyzed is under brackets. C. Box-n-Whisker plot showing fluorescence intensity of EB1-GFP at microtubule plus ends in the presence of 
purified EB1-GFP (100 nM) and increasing amounts of CN45 peptide as indicated. Figure was generated with PRISM 6.0. Shown is one 
representative experiment out of 3. Number of comets appearing over 30 minutes is under brackets. Right panel : Kymographs representing 
MT assembly in the presence of tubulin (15 µM), EB1-GFP (100 nM) and increasing amounts of CN45 peptide. Tubulin and EB1-GFP are 
detected by fluorescence (tubulin in red and EB1-GFP in green). Shown is one representative out of 3 independent experiments.
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In vitro studies were conducted to further explore 
the consequence of ATIP3-EB1 interaction in a cell-
free system. Using dual-color time-lapse total internal 
reflection fluorescence (TIRF) microscopy, we analyzed 
fluorescence intensity of purified EB1-GFP in the 
presence of dynamic ATTO-565 labeled microtubules and 
increasing amounts of CN45 peptide, that directly binds 
EB1 in vitro. As shown in Figure 5C, CN45 even in high 
molar excess had no significant effect on EB1 comets 
intensity, indicating that ATIP3-EB1 interaction in vitro 
is not sufficient to regulate EB1 localization at growing 
MT ends. Accordingly, MT dynamic instability parameters 
measured in vitro were not modified in the presence of 
EB1-interacting peptide CN45 (Figure 5C, Supplementary 
Table S2). Together, these studies suggest that negative 
regulation of EB1 at the MT plus ends by ATIP3 may 
require the presence of additional cellular components or 
involve post-translational modifications.
A novel model for negative regulation of EB1 at 
growing MT ends
Our data support a model in which cytosolic 
ATIP3-EB1 complexes slower the dynamic association 
of EB1 on growing MT ends, without affecting EB1 free 
diffusion and with no major alteration of its recognition 
site. In ATIP3-silenced cells, EB1 turnover is faster and 
EB1 is more prone to accumulate at plus ends together 
with its interacting partners, therefore leading to increased 
MT dynamic instability and subsequent increase in cell 
polarity. 
Recent studies conducted in developing neurons 
have shown that MAP1B and tau, two stabilizing MAPs 
that decorate MTs, also interact with EB1/3 and negatively 
regulate their accumulation at growing MT ends [22, 23]. 
A sequestration model has been proposed in which EB1 
is retained in the cytosol by interaction with MAP1B [22] 
or immobilized by elevated levels of tau proteins [23]. Of 
note, quantitative proteomics studies performed in NIH-
3T3 [24], UO2S [25] and HeLa [26] human cell lines have 
revealed high EB1 protein copy number (4.105 to 1.106 
molecules per cell) compared to ATIP3 (from undetectable 
to 300 or 1000 times less abundant than EB1), making it 
unlikely that ATIP3 sequesters EB1 in the cytosol. Arguing 
against a sequestration mechanism, FRAP analyses of 
EB1-GFP recovery indicate that ATIP3 silencing does not 
modify free mobility of EB1 in the cytosol. Our in vitro 
studies, showing that the purified CN45 peptide has no 
significant effect on EB1 comets intensity, further rule 
out the possibility that direct ATIP3-EB1 interaction may 
be responsible for decreased EB1 comets at MT ends. 
Together, our findings favor a novel mechanism by which 
ATIP3 interacts with EB1 in the cytosol and indirectly 
slowers its turnover on growing MT ends, thereby leading 
to decreased MT dynamics and cell polarity.
Given the potent tumor suppressor effects of ATIP3, 
these findings may have clinical relevance in the field of 
cancer. Indeed, EB1 overexpression has been reported 
in hepatocellular carcinoma [27], breast cancer [28], 
colorectal carcinoma [29, 30] and glioblastoma [31] and 
is associated with tumor progression and reduced survival 
of the patients [27, 31]. Decreasing EB1 association with 
its binding site at MT ends, with subsequent decrease in 
MT dynamics and cell polarity, may thus represent an 
interesting therapeutic option. Among the wide variety of 
EB1 partners, only few have been recognized as tumor 
suppressors [5]. The major tumor suppressor Adenomatous 
Polyposis Coli (APC) is a well-known EB1 interacting 
protein that paradoxically cooperates - rather than 
competes - with EB1 during mitosis and cell migration 
[32-34]. The Cylindromatosis CYLD tumor suppressor 
is another EB1-interacting +TIP that also acts in concert 
with EB1 to regulate MT dynamics and cell migration 
[35]. Results presented here provide the first evidence 
for negative regulation of EB1 dynamic association at 
MT ends by cytosolic interaction with a tumor suppressor 
protein. This study extends our knowledge of EB1 
regulation at growing MT ends and may have important 
implications in the field of cancer, in particular for 
aggressive tumors showing ATIP3 deficiency.
MATERIALS AND METHODS
Cell lines
Human breast cancer cell lines MCF7, HC7 (MCF7 
cells stably expressing endogenous levels of GFP-ATIP3) 
and D3H2LN, as well as SV-MRC5 lung fibroblasts, 
HeLa and RPE-1 cells were described previously [15, 
17]. MCF7, SV-MRC5-SV and RPE-1 cells express 
undetectable levels of ATIP3, whereas HeLa cells 
express endogenous ATIP3 [15, 17]. Cells were routinely 
authenticated by morphologic observation and tested for 
absence of mycoplasma contamination using MycoAlert 
Assay detection kit (Lonza, France).
Plasmids constructs and transfections
Plasmids encoding GFP-ATIP3, mCh-ATIP3, 
GFP-D1, GFP-D2 and GFP-D3 were described elsewhere 
[17]. GFP-fused D2 fragments and deletion mutants were 
obtained by PCR-amplification of ATIP3 sequence or 
Site-Directed Mutagenesis using oligonucleotides shown 
in Supplementary Table S3. Expression vectors encoding 
GST-EB1, GST-EB1-C, GST-EB1-N and GST-EB1-∆Ac 
were gifts of Dr Anna Akhmanova (Utrecht University, 
The Netherlands). EB1-GFP and GFP-CLIP-170 
constructs were provided by Dr Franck Perez (Institut 
Curie, Paris, France). GFP-MCAK and GFP-MCAK-
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3E were kindly provided by Dr Michel Steinmetz (Paul 
Scherrer Institute, Switzerland). All cDNA constructs 
were transfected (1 to 2 µg) for 24h using Dreamfect (Oz 
Biosciences) or X-treme Gene 9 (Roche).
ATIP3-specific siRNA [15], EB1-specific siRNA 
(on-target plus smart pool, NM_012325) and scrambled 
siRNA were from Dharmacon (ThermoFisher Scientific). 
All siRNAs (50 nM) were transfected using lipofectamine 
2000 (Invitrogen) and silencing efficiency was evaluated 
by immunoblotting using rabbit anti-MTUS1 antibodies 
(ARP44419; Aviva Systems, CA, USA) and rat anti-EB1 
(KT51; Santa Cruz).
GST pull-down assays and immunoprecipitations
Purification of GST fusion proteins and GST 
pull-down assays from extracts of HeLa cells or MCF7 
transiently expressing GFP fusion proteins were performed 
as described [3, 20] using 15-30 µg of GST or GST-EB1 
beads per experimental condition. Immunoblotting was 
using rabbit anti-MTUS1 (ARP44419, Aviva Systems) 
(1:1000) or monoclonal anti-GFP antibodies (clone 
7.1/13.1, Roche) (1:3000).
For in vitro interaction, chemically synthesized 
peptides CN45 and CC coupled to FITC were purchased 
from GL Biochem (Shanghai, China). Purified peptides 
were incubated for 1h at room temperature with GST- or 
GST-EB1 beads in 50mM HEPES containing 150mM 
NaCl, 0.01% Triton X100 (pH 7.4) then washed in 
the same buffer. Interaction was assessed by FITC 
fluorescence measurement using Fusion Universal 
Microplate Analyzer (Packard BioScience) and with 
Typhoon™ system (Amersham Biosciences) following 
15% SDS-PAGE.
For immunoprecipitation, cell lysates were 
incubated for 2h at 4°C with 4µg of mouse monoclonal 
anti-GFP (Roche), or mouse monoclonal anti-mCh 
(Clontech) antibodies prior to incubation with G protein-
sepharose beads. Bound proteins were detected by 
immunoblotting as described above.
Immunofluorescence and live cell imaging
Transfected RPE-1 cells were fixed with ice-
cold methanol and incubated as described with human 
anti-alpha-tubulin clone F2C [17], rat anti-EB1 (Santa 
Cruz) or mouse anti-GFP (Roche). Linescan analyses of 
fluorescence intensity were performed on a 5 µm line 
along the length of MT plus end [17]. Results shown are 
representative of 3 to 5 independent experiments. For 
quantification of comet number, 5 different areas of at 
least 5 single cells were analyzed in 3 to 5 independent 
experiments. 
For live cell imaging, SV-MRC5 co-transfected 
for 24h with mCh-ATIP3 and EB3-GFP were imaged 
by spinning disc confocal microscopy as described in 
Supplementary Methods. Images were acquired in a 
stream mode at 500 ms exposure time. 
For backtracking experiments, HC7 [17] were 
imaged using TIRF videomicroscopy as described in 
Supplementary Methods. Images were acquired in a 
stream mode at 100 ms exposure time. 
TIRF microscopy for in vitro studies
Perfusion chambers were functionalized with 
silane-PEG-biotin (Laysanbio) coverslips and silane-PEG 
(Creative PEGwork) glass slides as described [36]. The 
flow cell was firstly perfused with neutravidin (25 µg/
ml in 1% BSA/BRB80 (80 mM PIPES, 1 mM GTP, 1 
mM MgCl2, 1 mM EGTA, pH 6.75) and secondly with 
GMPCPP-stabilized, ATTO-565 labelled microtubule 
seeds. Microtubules assembly was performed at 32°C 
from 15 µM brain tubulin (containing 20% ATTO 
565-labeled tubulin) in the presence of 100 nM EB1-GFP 
and 0, 0.05 µM or 1 µM CN45 peptide (GL Biochem, 
Shanghai, China) in BRB80 buffer supplemented with 
4 mM DTT, 1% BSA, 50 mM KCl, 1 mg/ml glucose, 
70 µg/ml catalase, 580 µg/ml glucose oxydase, 0.1 % 
methylcellulose (4,000 centipoise). Dual-color time-
lapse imaging was performed on an inverted Eclipse Ti 
(Nikon) microscope with an Apochromat 60X1.49 N.A 
oil immersion objective (Nikon), equipped with an ilas2 
TIRF system (Roper Scientific), a cooled charged-coupled 
device camera (EMCCD Evolve 512, Photometrics) and 
controlled by the MetaMorph 7.7.5 software (Molecular 
Devices). For excitation we used 491- and 561-nm lasers. 
Time-lapse imaging was performed at 1 frame per 2 s with 
an 80-ms exposure time, during 30 minutes.
The image analysis was performed with ImageJ 
software, version 1.43u (W. Rasband, NIH. USA). The 
comet fluorescence intensities were measured over the 
tubulin polymerization periods using kymographs with 
background subtraction (protocol based on [8]). The 
average fluorescence intensity at microtubule growing 
ends was measured in the green channel with a 5-pixel-
wide line. Only comet fluorescence intensity differences 
superior to one background standard deviation were 
included in the calculation. Comparisons of fluorescence 
intensities with and without CN45 were calculated from 
experiments performed with the same acquisition set-
up and laser intensity. Microtubule dynamic parameters 
were determined on kymographs using Image J software, 
version 1.43u (W. Rasband, NIH. USA). Statistical 
analyses were done with Prism 6.0 (GraphPad software, 
USA).
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Fluorescence recovery after photobleaching 
(FRAP) analysis
HeLa cells were co-transfected with appropriate 
siRNA (72h) and EB1-GFP (24h). FRAP analyses were 
performed after bleaching MT ends, or selected cytosolic 
regions, and recovery was measured as described in 
Supplementary informations. To calculate the recovery 
of EB1-GFP fluorescence after photobleaching, the fit of 
the fluorescence decay was subtracted to the normalized 
curve to obtain a curve with only the mean fluorescence 
recovery. This curve could be fitted with the first-order 
exponential decay with a robust fitting routine: y = (y0 - 
plateau) * exp(-krecovery*x) + plateau, where y is normalized 
intensity, y0 is the initial fluorescence value, plateau is the 
y value at infinite times, (y0 - plateau) is the span of the 
reaction, krecovery is the reaction constant and x is the time. 
Half-time of recovery was calculated as ln(2)/ krecovery. 
Association time (Tau) was calculated as 1/ krecovery.
Proximity ligation assay (PLA)
In situ PLA detection was carried out using 
DUOLINK II In Situ Far Red kit (Sigma-Aldrich, St 
Louis, USA). HeLa cells were transfected (72h) with 
appropriate siRNAs, fixed and incubated with rabbit anti-
MTUS1 (ARP44419, Aviva Systems, 1:300) and mouse 
anti-EB1 (clone 5, BD Bioscience, 1:1000) antibodies. 
Transfected RPE-1 cells (24h) were fixed with ice-cold 
methanol and incubated with rabbit anti-GFP (Roche, 
1:10000) and mouse anti-EB1 (clone 5, BD Bioscience, 
1:1000) antibodies. Cells were incubated with duolink 
PLA Probes anti-mouse PLUS and anti-rabbit MINUS 
(1:5) for 1h at 37°C and processed for ligation and rolling 
circle amplification (RCA) in the presence of cy5-labeled 
oligonucleotide probe according to manufacturer’s 
protocol. Imaging was performed using a Zeiss Axiovert 
200M fluorescence microscope with 100x oil objective 
and controlled using Metamorph 7.1.7 software. For 
quantification of RCP number, 5 different areas of at 
least 6 single cells from 3 independent experiments were 
analyzed.
Statistical analysis
Statistical analyses were done using GraphPad 
Prism software. Data in bar graphs (mean +/- SD) and dot 
plots were analyzed using two-tail unpaired t-test. p < 0.05 
was considered statistically significant. 
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